Miao Li1, Yu Cai1, Xi Chen1, Luyong Zhang1,2, Zhenzhou Jiang1,3,4, Qinwei Yu1. 1. New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China. 2. Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China. 3. Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, Nanjing 210009 China. 4. Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009 China.
Abstract
Background: Clinically, long-term use of tamoxifen (TAM) would lead to fatty liver disease in breast cancer patients, especially obese women. However, the exact mechanism of TAM-induced hepatic steatosis is still unclear. Meanwhile, there is no drug to prevent and treat it. Aims and Methods: In view of silent information regulator 1 (SIRT1) playing a key role in hepatic lipid metabolism regulation, this study was conducted to investigate whether SIRT1 is a potential therapeutic target for TAM-induced hepatic steatosis. In this study, obese female Wistar rats fed with high-fat diet (HFD) for 15 weeks were given TAM (4, 8 mg/kg, intragastric) for 14 days. In vitro, human hepatocarcinoma cell line HepG2 was used to establish a high-fat model with 50 μM oleic acid and TAM (10 μM) was treated simultaneously for 72 h. Results: The results showed that TAM was more likely to upregulate the expression of lipid synthetase that caused the increase of lipid content in HepG2 cells and rat liver. The expression of SIRT1 was downregulated both in vitro and in vivo. SIRT1 agonist SRT1720 (15 mg/kg, 30 mg/kg, i.p.) could resist TAM-induced hepatic lipid synthetase overexpression to relieve TAM-induced hepatic steatosis. Meanwhile, the upregulation of p-forkhead box O1 and LXRα induced by TAM was reversed by SRT1720. Conclusions: These results indicated that TAM-induced hepatic steatosis was based on SIRT1-p-FoxO/LXRα-sterol regulatory element binding protein 1c pathway under HFD condition. SIRT1 agonist might be a potential therapeutic drug to relieve this side effect. Highlights: Tamoxifen increased lipid synthesis and regulated lipid transport in HFD rat liver.p-FoxO1/LXRα-SREBP1c signaling was upregulated through the inhibition of SIRT1 in tamoxifen-induced hepatic steatosis under HFD condition.SIRT1 agonist SRT1720 could relieve tamoxifen-induced hepatic steatosis.
Background: Clinically, long-term use of tamoxifen (TAM) would lead to fatty liver disease in breast cancer patients, especially obese women. However, the exact mechanism of TAM-induced hepatic steatosis is still unclear. Meanwhile, there is no drug to prevent and treat it. Aims and Methods: In view of silent information regulator 1 (SIRT1) playing a key role in hepatic lipid metabolism regulation, this study was conducted to investigate whether SIRT1 is a potential therapeutic target for TAM-induced hepatic steatosis. In this study, obese female Wistar rats fed with high-fat diet (HFD) for 15 weeks were given TAM (4, 8 mg/kg, intragastric) for 14 days. In vitro, human hepatocarcinoma cell line HepG2 was used to establish a high-fat model with 50 μM oleic acid and TAM (10 μM) was treated simultaneously for 72 h. Results: The results showed that TAM was more likely to upregulate the expression of lipid synthetase that caused the increase of lipid content in HepG2 cells and rat liver. The expression of SIRT1 was downregulated both in vitro and in vivo. SIRT1 agonist SRT1720 (15 mg/kg, 30 mg/kg, i.p.) could resist TAM-induced hepatic lipid synthetase overexpression to relieve TAM-induced hepatic steatosis. Meanwhile, the upregulation of p-forkhead box O1 and LXRα induced by TAM was reversed by SRT1720. Conclusions: These results indicated that TAM-induced hepatic steatosis was based on SIRT1-p-FoxO/LXRα-sterol regulatory element binding protein 1c pathway under HFD condition. SIRT1 agonist might be a potential therapeutic drug to relieve this side effect. Highlights: Tamoxifen increased lipid synthesis and regulated lipid transport in HFD rat liver.p-FoxO1/LXRα-SREBP1c signaling was upregulated through the inhibition of SIRT1 in tamoxifen-induced hepatic steatosis under HFD condition.SIRT1 agonist SRT1720 could relieve tamoxifen-induced hepatic steatosis.
Authors: Young-Joo Yang; Kang Mo Kim; Ji Hyun An; Dan Bi Lee; Ju Hyun Shim; Young-Suk Lim; Han Chu Lee; Yung Sang Lee; Jin-Hee Ahn; Kyung Hae Jung; Sung-Bae Kim Journal: Breast Date: 2016-05-27 Impact factor: 4.380
Authors: Ling Yan; Shuangli Guo; Marie Brault; Jamie Harmon; R Paul Robertson; Rizwan Hamid; Roland Stein; Elizabeth Yang Journal: Biochem J Date: 2012-06-01 Impact factor: 3.857
Authors: Rui E Castro; Duarte M S Ferreira; Marta B Afonso; Pedro M Borralho; Mariana V Machado; Helena Cortez-Pinto; Cecília M P Rodrigues Journal: J Hepatol Date: 2012-08-15 Impact factor: 25.083
Authors: Bora Lee; Eun-Ae Jung; Jeong-Ju Yoo; Sang Gyune Kim; Cheon-Beom Lee; Young Seok Kim; Soung Won Jeong; Jae Young Jang; Sae Hwan Lee; Hong Soo Kim; Baek Gyu Jun; Young Don Kim; Gab Jin Cheon Journal: Liver Int Date: 2020-04-07 Impact factor: 5.828
Authors: María E Fernández-Suárez; Joan C Escolà-Gil; Oscar Pastor; Alberto Dávalos; Francisco Blanco-Vaca; Miguel A Lasunción; Javier Martínez-Botas; Diego Gómez-Coronado Journal: Sci Rep Date: 2016-09-07 Impact factor: 4.379